Physicians' Academy for Cardiovascular Education

Snapshot Novel interventions in cardiovasculair disease

Held on Friday, August 24, 2012, Munich Germany

Feb. 1, 2013


PACE Snapshot Meeting Report

The first PACE Snapshot meeting 'Novel interventions in cardiovascular disease: Controversies & hot issues' was held on August 24, 2012 in Munich.The aim of this meeting was to provide expert physicians with a state of the art and comprehensive overview of different novel interventions in the future management of cardiovascular disease, and a platform for discussion, debate and exchange.

As an educational service to PACE members here short webcasts with each of the faculty members are provided to get a brief update on the key topics of the presentationst.
 

Webcasts (3 minute each)

 

  Webcast

ACS & Diabetes

Prof. John Betteridge , London about the current status of drugs targeting the hormone nuclear receptors, such as pioglitazone (PPAR-y) and aleglitazar (dual PPAR)

Webcast

Targeting CV risk:

View Prof. John Deanfield discuss the central role of the endothelium in detecting atherosclerosis and CV disease before its clinical stage and opportunities to evaluate the impact of new drug therapies.

Webcast • ESC 2012

HDL-c: Latest insights and opinion on CETP as target for intervention

Prof. Philip Barter, Sydney, Australia , with his opinion on the development of CETP inhibitors.

Webcast • ESC, 2012

ACS and Lipids: HDL Infusion and delipidation as standard treatment for ACS

Dr. Bryan Brewer, Washington, USA , about the potential role of HDL infusion in the coronary plaque to reduce residual CV risk in patients with ACS.

Webcast •

The future of hypertension management:The role of new interventions

Prof. Bryan Williams outlines some of the key areas of innovation in the management of high blood pressure

Webcast • ESC 2012

What is new in Anti-coagulation in AF and ACS

Prof. Freek Verheugt Amsterdam, NL about the potential role of NOACs as alternative to warfarin in the management of AF

 

Presentations
 

  Slides • 18-9-2012

ACS & Diabetes

Potential role of new antidiabetic therapies Presented by prof John Betteridge, University College London, United Kingdom At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 18-9-2012

HDL & ACS

HDL infusion and delipidation as standard treatment for ACS Presented by dr Bryan Brewer, Medstar Resaerch Institute, Washington, USA At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 18-9-2012

Inflammation: The link between risk factors and atherosclerosis?

Presented by professor Ulf Landmesser, University Hospital Zurich, Switzerland At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 13-9-2012

What is new and coming in anticoagulation and ACS, AF

Presented by professor Freek Verheugt, OLVG, Amsterdam, The Netherlands At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 13-9-2012

HDL raising therapies:

Latest insights and opinion on CETP as target for intervention. Presented by professo Philip Barter, The Heart Research Institute, Sydney, Australia At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 12-9-2012

LDL-c, Should we go lower?

Novel Therapies, Novel Promises? Presented by prof John Kastelein, Academic Medical Centre, Amsterdam At PACE Snapshot meeting, August 24, 2012 in Munich

Slides • 12-9-2012

The future of hypertension management

The role of new interventions Presented by Prof Bryan Williams, University College London At PACE Snapshot meeting, August 24, 2012 in Munich
 

Share this page with your colleagues and friends: